Key facts
- This page summarizes Christopher J. Reading's Form 4 filing for U S PHYSICAL THERAPY INC /NV (USPH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Feb 2026, 20:46.
Christopher J. Reading - 23 Feb 2026 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)
- Reporting relationship
- Chairman of the Board and CEO, Director
- Issuer ticker
- USPH
- Reported as of
- 23 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Feb 2026, 20:46:08 UTC
- Prior SEC filing
- 05 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kate Venturina, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher J. Reading filed Form 4 for U S PHYSICAL THERAPY INC /NV (USPH) on 25 Feb 2026.
Change
- Previous filing in this sequence was filed on 05 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001270356
Primary reporting owner
READING CHRISTOPHER J
- Relationship
- Chairman of the Board and CEO, Director
- Address
- 1300 W SAM HOUSTON PKWY S, SUITE 300, HOUSTON
- Signature
- /s/ Kate Venturina, as attorney-in-fact
- Signature date
- 25 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
USPH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- +22%
- Price
- $0.000000
- Shares after
- 139,088
- Date
- 23 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. The restrictions lapse in 15 equal quarterly installments of 1,562 shares beginning on May 20, 2026 and on each of March 6, May 20, August 20, and November 20 of each of the years 2026, 2027, 2028, and 2029 and 1,570 shares vesting on March 6, 2030
Footnote F2
Includes 54,946 shares, inclusive of those mentioned in Footnote 1, which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restriction lapse as follows: 4,152 shares vest on March 6, 2026; 4,464 shares vest on each of May 20, 2026, August 20, 2026, November 20, 2026 and March 6, 2027; 3,839 shares vest on each of May 20, 2027, August 20, 2027, and November 20, 2027; 3,847 shares vest on March 6, 2028; 2,827 shares vest on each of May 20, 2028, August 20, 2028, and November 20, 2028; 2,837 shares vest on March 6, 2029; 1,562 shares vest on each of May 20, 2029, August 20, 2029, and November 20, 2029 and 1,570 shares vest on March 6, 2030. Vesting is subject to his continued employment with the Company through each applicable vesting date.